Back to top
more

Celldex Therapeutics (CLDX)

(Delayed Data from NSDQ)

$34.78 USD

34.78
823,799

-2.77 (-7.38%)

Updated Aug 2, 2024 04:00 PM ET

After-Market: $34.75 -0.03 (-0.09%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Celldex (CLDX) Q4 Loss Narrows, Revenues Beat, Shares Up

Celldex (CLDX) reports narrower-than-expected loss in Q4 with sales also beating estimates. Moreover, shares rise in after-hours trading on Mar 7 following the results.

    AVEO Pharmaceuticals' (AVEO) Q4 Earnings: What's in Store?

    AVEO Pharmaceuticals (AVEO) launched its first drug, Fotivda, as first-line treatment for RCC in Europe in November. This is likely to have a favorable impact on fourth-quarter results.

      What's in the Cards for Merck KGaA (MKGAF) in Q4 Earnings?

      Merck's (MKGAF) Healthcare and Life Science segments are likely to drive sales in Q4. However, the company's oncology drug fails in a phase III gastric cancer study.

        What's in Store for Catalyst (CPRX) This Earnings Season?

        Investors focus will be on pipeline and regulatory updates during Catalyst's (CPRX) fourth-quarter earnings call.

          Is a Beat in the Cards for Celldex (CLDX) in Q4 Earnings?

          With no approved product in Celldex Therapeutics' (CLDX) portfolio, investor focus is on immuno-oncology pipeline.

            AbbVie's Upadacitinib Gains Breakthrough Therapy Designation

            AbbVie's (ABBV) atopic dermatitis (eczema) candidate, upadacitinib, gets breakthrough therapy status from the FDA.

              Amgen Announces Acceptance of MAA for Evenity in Europe

              Amgen's (AMGN) regulatory application seeking approval for Evenity as a treatment of osteoporosis gets EMA's acceptance.

                4 Reasons to Include Celldex (CLDX) Stock in Your Portfolio

                Celldex stock has been performing well for the last six months and the momentum is likely to continue in the near term.

                  TherapeuticsMD Submits NDA for VMS Candidate, Shares Rise

                  TherapeuticsMD (TXMD) announces submission of NDA to the FDA seeking approval of TX-001HR to treat vasomotor symptoms in post-menopausal women.

                    AbbVie's RA Candidate Meets Endpoints in 3rd Phase III Study

                    AbbVie's (ABBV) RA candidate, upadacitinib, achieves statistically significant improvement in patients in phase III monotherapy study comparing it to methotrexate.

                      Minerva Initiates Phase III Study on Schizophrenia Candidate

                      Minerva Neurosciences (NERV) initiates a phase III study to evaluate MIN-101 as monotherapy to treat negative symptoms in schizophrenia patients.

                        TherapeuticsMD Falls Despite Acceptance of NDA: Here's Why

                        TherapeuticsMD (TXMD) announces the acceptance of its resubmitted NDA for TX-004HR for treating dyspareunia as Class 2 response. A likely delay in approval drives shares down.

                          Shire's New Formulation of Oncaspar Gets Approval in Europe

                          Shire's (SHPG) marketing authorization application for a new (dried) formulation of its leukemia drug, Oncaspar receives approval from the European Commission.

                            Glaxo's Nucala Label Expansion Application Gets FDA Approval

                            GlaxoSmithKline's (GSK) application to include treatment of eosinophilic granulomatosis with polyangiitis in Nucala's label was approved by the FDA.

                              Celldex Begins Phase I Trial on Cancer Candidate CDX-1140

                              Celldex (CLDX) commences a phase I study on CDX-1140 for patients with advanced solid tumors. The study is designed to evaluate the safety and tolerability of the candidate at different dose levels.

                                Celldex (CLDX) Initiates Phase II Study on Cancer Candidate

                                Celldex (CLDX) enrolled the first patient in a phase II study on pipeline candidate, CDX-3379, to evaluate it in advanced head and neck squamous cell carcinoma patients.

                                  Celldex (CLDX) Q3 Loss Narrows, Revenues Beat, Shares Up

                                  Celldex Therapeutics, Inc. (CLDX) reported narrower-than-expected loss in Q3 and also beat estimates for sales. Shares rose in after-hours trading on Tuesday.

                                    Celldex (CLDX) to Report Q3 Earnings: What's in the Cards?

                                    With no approved product in Celldex Therapeutics' (CLDX) portfolio, investor focus will remain on immuno-oncology pipeline, which continues to show impressive results.

                                      Celldex Ends Phase II Enrollment for Breast Cancer Candidate

                                      Celldex (CLDX) announces completion of enrollment in METRIC, a phase IIb study, evaluating glembatumumab vedotin for breast cancer treatment.

                                        Celldex (CLDX) Q2 Loss Narrows, Revenues Beat, Shares Up

                                        Celldex Therapeutics, Inc. (CLDX) reported narrower-than-expected loss in Q2 and also beat estimates for sales. Shares rose in after-hours trading on Tuesday.

                                          What's in the Cards for Celldex (CLDX) this Earnings Season?

                                          With no approved product in Celldex Therapeutics's (CLDX) portfolio, investor focus will remain on immuno-oncology pipeline, which continues to show impressive results.

                                            Why Is Celldex (CLDX) Down 27% Since the Last Earnings Report?

                                            Celldex (CLDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                              Celldex's Immuno-Oncology Pipeline Continues to Impress

                                              On May 25, we issued an updated research report on Hampton, NJ-based Celldex Therapeutics, Inc. (CLDX).

                                                Celldex (CLDX) Q1 Loss In Line, Revenues Beat, Shares Up

                                                Celldex Therapeutics, Inc. (CLDX) posted first-quarter 2017 loss of 28 cents per share, which was in line with the Zacks Consensus Estimate

                                                  Celldex Therapeutics (CLDX) Q1 Earnings: What's in Store?

                                                  Celldex Therapeutics, Inc. (CLDX) is expected to report first-quarter 2017 results on May 4. Celldex's performance has been encouraging with a three-quarter average positive surprise of 8.06%.